

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 39/155</b>		(11) International Publication Number: <b>WO 98/02179</b>
A1		(43) International Publication Date: 22 January 1998 (22.01.98)
(21) International Application Number: PCT/CA97/00498 (22) International Filing Date: 11 July 1997 (11.07.97) (30) Priority Data: 08/679,065          12 July 1996 (12.07.96)          US (71) Applicants (for all designated States except US): CON- NAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, North York, Ontario M2R 3T4 (CA). VIROGENETICS CORPORATION [US/US]; 465 Jordan Road, Rensselaer Technology Park, Troy, NY 12180 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KLEIN, Michel, H. [CA/CA]; 16 Munro Boulevard, Willowdale, Ontario M2P 1B9 (CA). TARTAGLIA, James [US/US]; 7 Christina Drive, Schenectady, NY 12303 (US). CATES, George, A. [CA/CA]; 37 Pemberton Road, Richmond Hill, Ontario L4C 3T5 (CA). EWASYSHYN, Mary, E. [CA/CA]; Apartment 1506, 120 Torresdale, Willowdale, Ontario M2R 3N7 (CA). (74) Agent: STEWART, Michael, I.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TWO-STEP IMMUNIZATION PROCEDURE AGAINST THE PYRAMYXOVIRIDAE FAMILY OF VIRUSES USING RECOMBINANT VIRUS AND SUBUNIT PROTEIN PREPARATION

## (57) Abstract

An immunization strategy to provide protection against disease caused by infection with a paramyxoviridae virus, specifically respiratory syncytial virus (RSV) and parainfluenza virus, is described. A priming intranasal administration of a recombinant virus expressing at least one RSV or PIV protein or immunogenic sequence thereof first is made to the host followed by a booster administration of at least one purified RSV or PIV protein or immunogenic fragment thereof, which may be adjuvanted with alum. This immunization strategy provides a safe and effective means of controlling RSV and PIV infections. The strategy leads to a stronger protective immune response than other strategies and to the induction of a more balanced Th-1/Th-2 type response than previously attained. Novel recombinant poxviruses are provided containing nucleic acid encoding a paramyxovirus protein or immunogenic fragment thereof in a non-essential region of the poxvirus genome, specifically NYVAC-F and ALVAC-F, which produce the F glycoprotein of RSV.

Anti-RSV F Titres in the Sera of Mice  
Immunized with Different Prime / Boost Protocols

\* Placebo control animals (groups 6,7,8,) were immunized according to the protocol outlined in Table 1.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONTWO-STEP IMMUNIZATION PROCEDURE AGAINST THE  
PYRAMYXOVIRIDAE FAMILY OF VIRUSES USING RECOMBINANT  
5 VIRUS AND SUBUNIT PROTEIN PREPARATIONFIELD OF INVENTION

The present invention relates to the field of immunology and, in particular, to a vaccination  
10 procedure for protection of a host against disease caused by infection with a virus of the paramyxoviridae family, particularly respiratory syncytial virus (RSV).

BACKGROUND TO THE INVENTION

15 Human parainfluenza virus type 1, 2, 3 and human respiratory syncytial virus (RSV) have been identified as the major viral pathogens responsible for severe respiratory tract infections in infants and young children (ref. 1 to 3 - Throughout this specification,  
20 various references are referred to in parenthesis to more fully describe the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately following the claims. The disclosures of  
25 these references are hereby incorporated by reference into the present disclosure). RSV has also been reported to cause significant morbidity in immunocompromised individuals and the elderly. Globally 65 million infections occur every year resulting in  
30 160,000 deaths (ref. 4). In the USA alone, 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection (refs. 5, 6). Inpatient and ambulatory care for children with RSV infections has been estimated to  
35 cost in excess of \$340 million each year in the USA (ref. 7). Severe lower respiratory tract disease due to RSV infection predominantly occurs in infants two to six months of age (ref. 8). The World Health Organization

(WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory committees have ranked RSV second only to HIV for vaccine development while the preparation of an efficacious PIV-3 vaccine is ranked in the top ten vaccines considered a priority for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing paramyxoviridae infections including RSV have provided the incentive for aggressively pursuing the development of efficacious RSV vaccines.

RSV is a member of the Paramyxoviridae family of the pneumovirus genus (ref. 2). The two major protective antigens of RSV are the envelope fusion (F) and attachment (G) glycoproteins (ref. 9).

In addition to the antibody response generated by the F and G glycoproteins, human cytotoxic T-cells have been shown to recognize the F protein RSV matrix (M) protein, nucleoprotein (N), small hydrophobic protein (SH) and nonstructural protein (NS) (ref. 10), produced following RSV infection. For PIV-3, the protective immunogen are the hemagglutinin-neuramidase (HN) protein and the fusion (F) protein.

Previous attempts to produce a safe and effective RSV vaccine were unsuccessful. Production of live attenuated RSV vaccines has had limited success. The mutants prepared to date have all been either over-attenuated, virulent or genetically unstable. A formalin-inactivated (FI) RSV vaccine developed in the 1960's failed to provide adequate protection in clinical trials (refs. 8, 11, 12). In fact, immunization of seronegative infants with the FI-RSV vaccine resulted in the exacerbation of RSV disease (immunopotential) in some vaccinees following exposure to wild type virus. Identification of the major immunoprotective antigens of RSV has provided the scientific rationale for pursuing a

subunit approach to RSV vaccine development. However, efficacy of the RSV subunit vaccines tested to date have been inconsistent (ref. 12). There is also conflicting reports in the literature on the ability of an alum-  
5 adjuvanted RSV vaccine containing the F protein purified from virus infected cells by immunoaffinity chromatography (PFP-1) to cause enhanced pulmonary pathology (immunopotential) following live virus challenge (ref. 13 and 14). There is a definite  
10 requirement for the development of a safe and efficacious RSV vaccine.

One of the main obstacles in developing a safe and effective RSV vaccine has been to produce a vaccine formulation that can elicit a protective immune response  
15 without causing exacerbated disease. Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in  
20 cell-mediated responses may contribute to immunopotential (ref. 15). Enhanced histopathology observed in mice that were immunized with the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10 (ref.  
25 16). Experimental results indicated that induction of a Th-2 type response may play a role in disease potentiation. BALB/c mice given live virus intranasally or intramuscularly elicited a Th-1 type response, whereas FI-RSV induced a Th-2 type of response. These  
30 results were recently substantiated by the finding that BALB/c mice that were immunized with the FI-RSV vaccine had a marked increase in the expression of mRNA (from cells in the bronchoalveolar lavage fluid) for the Th-2 cytokines IL-5 and IL-13 (ref. 17).

35 Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza

virus infection are being pursued. Clinical trial results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 33, 34, 35). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later became infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focussed on candidate PIV-3 vaccines (ref. 36) with significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus (refs. 37, 38, 39, 40).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 41, 42, 43). The HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, 2 and 3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one PIV type are not cross-protective. Thus, an effective PIV



subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses.

Antibody to either glycoprotein is neutralizing in vitro. A direct correlation has been observed between  
5 the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus  
10 using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection  
15 models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 44, 45, 46, 47, 48). The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have  
20 been produced in insect cells using the baculovirus expression system and by the use of vaccinia virus and adenovirus recombinants (refs. 49, 50, 51, 52, 53). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a  
25 chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Patent Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

30 The construction of the recombinant poxviruses is described in a number of granted United States patents, including U.S. Patents Nos. 4,603,112, 4,769,330, 4,722,848 and 5,110,587 relating to various recombinant virus constructs, U.S. Patents Nos. 5,453,364, 5,225,336  
35 and 5,155,020 relating to attenuated recombinant vaccinia virus constructs and U.S. Patent No. 5,174,993 .

relating to recombinant avipox virus constructs. The disclosure of these patents are incorporated herein by reference.

Live recombinant poxviruses expressing the relevant  
5 viral proteins may be used alone or as priming immunogens in a prime/boost regime with the subunit vaccine. Despite having promising attributes as a "universal" immunization vehicle, safety issues have provided a concern for the re-introduction of vaccinia  
10 virus as an immunizing agent. These concerns stem from complications observed during the Smallpox Eradication Program (ref. 18). From one perspective, the safety issues surrounding the use of vaccinia-based vaccine candidates have been addressed with the development of  
15 the NYVAC and ALVAC vectors.

The NYVAC strain was derived from the vaccinia virus Copenhagen strain by the precise deletion of 18 ORFs encoding functions implicated in the pathogenicity of orthopoxviruses, as well as host-range regulatory  
20 functions governing the replication competency of these viruses on cells from certain species (ref. 19). General biological properties of NYVAC include: 1] a highly debilitated replicative capacity on cells derived from mice, swine, equids, and humans; 2] the ability to  
25 replicate with wildtype efficiency on primary chick embryo fibroblasts; and 3] a highly attenuated phenotype in immunocompetent and immunocompromised animal systems used historically to assess the virulence of vaccinia virus strains (ref. 19). Despite these highly  
30 attenuated properties, NYVAC has been shown to function effectively as an immunization vehicle (ref. 19, 20). These properties are consistent with NYVAC providing a safer alternative to existing vaccinia virus vaccine strains for developing vector-based vaccine candidates.  
35 Due to the attenuation profile of NYVAC, the Recombinant DNA Advisory Committee of the National

Institutes of Health has reduced the biological containment level of this virus from BSL-2 to BSL-1. It is the only member of the *Orthopoxvirus* genus accorded a BSL-1 biocontainment level.

5       The basic vaccinia virus vector technology has been extended to other members of the poxvirus family. Extension to the *Avipoxvirus* genus, in particular fowlpoxvirus (FPV), was targeted for species-specific applications in the poultry industry (ref. 21). Studies  
10 with a FPV recombinant expressing an immunogen from a mammalian pathogen (the rabies virus glycoprotein G), however, demonstrated the ability of this recombinant to elicit immune responses in a number of non-avian species (ref. 22), thus establishing these viruses as viable  
15 candidates for developing non-replicating vector-based vaccine candidates for veterinary and human application. The inability of the *Avipoxviruses* to productively replicate in non-avian species provides an exquisite safety barrier against the occurrence of vaccine-  
20 associated and vaccine-induced complications.

Subsequent studies with canarypoxvirus (CPV)-based recombinants in non-avian species also demonstrated their utility as immunization vehicles (refs. 23, 24). In this regard the canarypoxvirus-based recombinants  
25 were found superior to similar FPV recombinants and equivalent to thymidine-kinase mutants of replication-competent vaccinia virus recombinants (refs. 19, 24). A plaque-cloned isolate of CPV was derived from the vaccine strain Kanapox and designated ALVAC (ref. 19).

30       ALVAC, like NYVAC, has demonstrated a highly attenuated phenotype in a number of animal systems comparing existing vaccinia virus vaccine strains (ref. 19). The Recombinant DNA Advisory Committee has reduced the biological containment for ALVAC to BSL-1.  
35 Furthermore, ALVAC has been shown to be an effective immunization vehicle in a number of non-avian species

including humans (ref. 25). The concept of using a non-replicating vector in humans was supported by the results of phase I clinical trials using an ALVAC-based rabies G (ref. 26) and an ALVAC-HIV-1<sub>MN</sub> env (ref. 27) recombina<sup>5</sup> nt. In each study, the ALVAC-based recombinant elicited antigen-specific immune responses the heterologous antigen. Thus, the use of either ALVAC or NYVAC recombinants expressing the pertinent RSV proteins represents a promising approach for RSV vaccine<sup>10</sup> development.

#### SUMMARY OF THE INVENTION

The present invention provide a novel immunization strategy to provide protection against disease caused by<sup>15</sup> infection and members of the Paramyxoviridae family, particularly respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The immunization strategy provided herein leads to a stronger protective immune response than other strategies.

<sup>20</sup> According to one aspect of the invention, there is provided a method of immunizing a host against disease caused by infection by a paramyxoviridae viruses, which comprises:

initially administering to the host an<sup>25</sup> immunoeffective amount of a recombinant virus expressing at least one paramyxoviridae virus protein or immunogenic fragment thereof, and

subsequently administering to the host an immunoeffective amount of at least one purified<sup>30</sup> paramyxoviridae protein or immunogenic fragment thereof of the same at least one paramyxoviridae protein as used in the initial administration, to achieve a paramyxovirus specific protective immune response in the host.

<sup>35</sup> The immune response which is achieved in the host by the method of the invention preferably includes the

production of virus specific neutralizing antibodies and virus specific cytotoxic T-cell responses. The immunization strategy employed herein priming with the recombinant virus and boosting with the protein  
5 preparation leads to the induction of a more balanced anti-F IgG1/IgG2a response than previously obtained, which sets the stage for a more Th-1 type response. In addition, the immunization strategy may lead to a more balanced Th-1/Th-2 type response than previously  
10 attained.

While the invention is broadly effective with members of the paramyxoviridae family, the invention is preferably effective to provide protection against respiratory tract diseases caused by respiratory  
15 syncytial virus (RSV) and parainfluenza virus (PIV), in particular respiratory syncytial virus.

The recombinant virus may be a pox virus and may express at least one of the F, G and M proteins of RSV or an immunogenic fragment thereof, particularly the F  
20 glycoprotein of RSV.

The purified RSV protein or immunogenic fragment thereof employed in the second or booster administration may be selected from the group consisting of the F, G and M proteins of RSV or immunogenic fragments thereof  
25 and may comprise a mixture of two or three of these RSV proteins or the immunogenic fragments thereof.

The at least one purified paramyxoviridae protein or immunogenic fragment thereof, including mixtures of the F, G and/or M proteins of RSV or immunogenic  
30 fragments thereof, may be administered with an adjuvant or immunomodulator, including alum.

In a further aspect of the present invention, there is provided a novel recombinant poxvirus containing therein a nucleic acid sequence encoding a  
35 paramyxoviridae protein or immunogenic fragment thereof

in a non-essential region of the recombinant virus genome.

The poxvirus may be a vaccinia virus, in particular one in which non-essential virus-encoded genetic functions have been inactivated therein so as to provide an attenuated vaccinia virus. In one embodiment, such attenuated vaccinia virus may contain a nucleic acid sequence encoding the F glycoprotein of respiratory syncytial virus (RSV). One such recombinant vaccinia virus is provided herein and is designated virus vP1000 (NYVAC-F) having the ATCC Deposit No. VR-2540.

Alternatively, the poxvirus may be an avipox virus, which may be a fowlpox virus, which is non-virulent in humans. In one embodiment, the nucleic acid sequence encodes the F glycoprotein of respiratory syncytial virus (RSV). One such recombinant avipox virus is provided herein and is designated virus vCP181 (ALVAC-F) having ATCC Deposit No. VR-2541.

The present invention further comprises the use of such recombinant poxvirus as a medicine or in the manufacture of a medicament for immunization.

#### BRIEF DESCRIPTION OF DRAWINGS

Figure 1, containing panels a and b, shows SDS-PAGE analysis of a purified RSV A subunit preparation using acrylamide gels stained with silver, under both reduced (panel (a)) and non-reduced (panel (b)) conditions;

Figure 2, containing panels a, b, c and d, shows Western blot analysis of a purified RSV subunit preparation under reduced conditions;

Figure 3, containing panels a, b, c and d, shows Western blot analysis of a purified RSV subunit preparation under non-reduced conditions;

Figure 4 shows the nucleotide sequence of the recombinant pox virus vCP181 (SEQ ID No. 21) (ALVAC-F), an H6-promoted RSV-F gene insertion with flanking

sequences. The H6 promoter commences at position 202. The RSV-F gene starts at position 326 and ends at position 2048;

Figure 5 shows the nucleotide sequence of the 5 recombinant poxvirus virus vP1000 (SEQ ID No: 22) (NYVAC-F), an H6 promoted RSV-F gene insertion with flanking sequences. The H6 promoter begins at position 575. The RSV-F gene starts at position 699 and ends at position 2421;

10 Figure 6, containing panels A, B and C, shows the anti-RSV F antibody titres in the sera of mice immunized with different prime/boost protocols, as detailed in Table 1 below;

Figure 7 shows the plaque reduction titres in the 15 sera of mice immunized with different prime/boost protocols, as detailed in Table 1 below; and

Figure 8 shows the cytotoxic T lymphocyte responses in mice immunized with different prime/boost protocols, as detailed in Table 1 below.

20

#### GENERAL DESCRIPTION OF THE INVENTION

The present invention relates to methods of immunization comprising an initial administration of a recombinant virus expressing at least one 25 paramyxoviridae virus protein or immunogenic fragment thereof and a subsequent administration of at least one protein or fragment thereof of the same protein of the paramyxoviridae virus. The recombinant virus vector expressing at least one paramyxoviridae virus protein 30 may itself be unable to confer protection. The at least one protein may comprise a mixture of RSV proteins such as G glycoprotein, F glycoprotein, M protein and heterodimers and oligomeric forms of the F and G proteins. Thus, the subsequent administration may be of 35 a subunit preparation isolated from RSV viral concentrates.

Referring to Figures 1 to 3, there is shown an analysis of the composition of a RSV subunit preparation by SDS-PAGE analysis (Figure 1) and Western blot (Figures 2 and 3). The isolation of this preparation from RSV viral concentrate is described below. A typical composition of the RSV subunit preparation determined by densitometric scanning is:

	G glycoprotein (95 kDa form)	10%
	F <sub>1</sub> glycoprotein (48 kDa)	30%
10	M protein (31 kDa)	23%
	F <sub>2</sub> glycoprotein (23 kDa)	19%

when analyzed under reducing conditions by SDS-PAGE and silver staining.

As described above the primary (priming) immunization may be by administration of a recombinant virus expressing at least one paramyxoviridae virus protein. The recombinant virus may be a pox virus modified to contain a gene encoding at least a portion of the paramyxoviridae virus protein, such as the RSV F protein. The poxvirus may be attenuated for the usually mammalian host by modification of regions of the poxvirus genome necessary for virulence to produce, for example, a NYVAC-F recombinant virus, such as vP1000. Figure 5 shows the nucleotide sequence of vP1000. In an alternative embodiment, the poxvirus may be virus such as an avipox virus that does not replicate in mammalian hosts, such as a ALVAC-F recombinant virus, such as vPC181. Figure 4 shows the nucleotide sequence of vPC181.

Recombinant avipox viruses containing the gene encoding the F protein of RSV were constructed and used to immunize mice according to the protocols shown in Table 1. Total anti-F IgG, IgG1 and IgG2 antibodies were measured in murine sera and the results are shown in Figure 6. The sera from animals that were primed with the ALVAC-F recombinant virus and boosted either



with the ALVAC-F recombinant virus or the subunit preparation had anti-F IgG1/IgG2a ratios of approximately 1:1. This is in contrast to the anti-RSV F IgG1/IgG2a ratios obtained in mice that were primed 5 and boosted with formalin-inactivated RSV (8:1) or subunit vaccine (11:1). The induction of IgG2A in mice is indicative of a Th1 immune response.

The sera of mice primed with the ALVAC-F recombinant virus and boosted with the RSV proteins as a 10 subunit preparation contained high levels of virus neutralizing antibodies as shown by plaque reduction titres (Figure 7). Mice primed with the poxvirus recombinant and then boosted with RSV proteins produced RSV-specific cytotoxic T cells as shown in Figure 8.

15 Of significance is that mice primed with recombinant pox expressing the RSV F protein and boosted with RSV proteins were protected from challenge with live RSV as shown in Table 2. In particular, mice primed and boosted with ALVAC-F recombinant virus had 20 detectable virus in their lungs whilst no virus could be detected in the lungs of mice that were primed with ALVAC-F and boosted with RSV proteins or an RSV subunit preparation.

The invention extends to the use of a recombinant 25 virus expressing at least one paramyxoviridae virus protein for primary immunization (priming) of a host and the subsequent use of at least one paramyxoviridae virus protein for boosting said host to protect said host against disease caused by paramyxoviridae.

30 The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, immunogenic and protective. The quantity to be administered depends on the subject to be treated, including, for example, 35 the capacity of the immune system of the individual to synthesize antibodies, and, if needed, to produce a

cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms to milligrams of the proteins or fragments thereof and about  $10^5$  -  $10^9$  pfu of the combinant virus. The dosage may also depend on the route of administration and will vary according to the size of the host.

Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in

increasing antibody responses to diphtheria and tetanus toxoids is well established and a HBsAg vaccine has been adjuvanted with alum. While the usefulness of alum is well established for some applications, it has 5 limitations. For example, alum is ineffective for influenza vaccination and usually does not elicit a cell mediated immune response. The antibodies elicited by alum-adjuvanted antigens are mainly of the IgG1 isotype in the mouse, which may not be optimal for protection by 10 some vaccinal agents.

A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include aluminum phosphate, aluminum hydroxide, QS21, Quil A, derivatives and components thereof, calcium phosphate, 15 calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid, a muramyl dipeptide, polyphosphazene, a lipoprotein, ISCOM matrix, DC-Chol, DDA, and other adjuvants and bacterial toxins, components and derivatives thereof as, for example, 20 described in U.S. Application No. 08/481,878, (WO 95/34323) assigned to the assignee hereof and the disclosure of which is incorporated herein by reference thereto. Under particular circumstances adjuvants that induce a Th1 response are desirable.

25 The at least one purified paramyxovirus protein or immunogenic fragment thereof used in the booster administration may be provided in any convenient manner. For example, the protein, proteins or immunogenic fragments may be extracted from cellular material, such 30 as by detergent extraction, and may be purified by affinity chromatography, as described, for example, in aforementioned U.S. Patent Application No. 07/773949, WO 91/00104. Alternatively, an immunoaffinity purification procedure may be used.

35 Alternatively, the protein, proteins or immunogenic fragments thereof may be prepared recombinantly by

expression of the protein or fragment thereof from a suitable vector with subsequent purification of the expressed material. Suitable vectors and expression systems are described, for example, in WO 87/04185.

5 In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell may be used for the expression of the relevant genes in expression systems. The vector ordinarily carries a replication site, as  
10 well as marking sequences which are capable of providing phenotypic selection in transformed cells. Details concerning the nucleotide sequences of promoters are known, enabling a skilled worker to ligate them functionally with the relevant genes. The particular  
15 promoter used will generally be a matter of choice depending upon the desired results. Hosts that are appropriate for expression of the relevant genes and immunogenic fragments thereof include bacteria, eukaryotic cells, fungi, yeast or the baculovirus  
20 expression system may be used.

It may be preferred to make the relevant protein or immunogenic fragment thereof, particularly when the naturally occurring protein as purified from a culture may include trace amounts of toxic materials or other  
25 contaminants. This problem may be avoided by using recombinantly produced protein in heterologous systems which can be isolated from the host in a manner to minimize contaminants in the purified material.

### 30 **Biological Deposits**

Certain recombinant pox viruses that are described and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 12301 Parklawn Drive, Rockville, Maryland 20852, USA pursuant  
35 to the Budapest Treaty and prior to the filing of this application. Samples of the deposited viruses will

become available to the public and all restrictions imposed on access to the deposits will be removed upon grant of a patent on this application. Samples of the deposit will be prepared if the depository is unable to  
5 dispense viable samples. The invention described and claimed herein is not to be limited in scope by recombinant viruses deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar recombinant virus  
10 are within the scope of the invention.

#### Deposit Summary

Recombinant Virus	ATCC Designation	Date Deposited
vP1000 (NYVAC-F)	VR-2540	July 12, 1996
cVP181 (ALVAC-F)	VR-2541	July 12, 1996

15

#### EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for  
20 purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are  
25 intended in a descriptive sense and not for purposes of limitations.

#### Example 1

This Example describes the generation of the ALVAC  
30 recombinant containing the RSV-F gene.

Plasmid pSKF7, containing the coding sequence for the RSV type A fusion glycoprotein (RSV-F), was obtained

from Institute Merieux, Lyon, France. RSV-F coding sequences, from plasmid pSKF7, were placed under control of a vaccinia virus promoter by joining fragments which had been amplified by the polymerase chain reaction (PCR) (ref. 28). The modified vaccinia virus early/late H6 promoter (ref. 29), followed by the 5' base pairs of the RSV F gene, was amplified by PCR from plasmid pRW825 containing the H6 promoter sequence. Oligonucleotide primers RW325 (5'-GATTGAGGATCCTTAATTAATTAGTGATAC-3') (SEQ ID No: 1) and RW326 (5'-TGCATTTGCTTTGAGGATTAGCAACTCCATTACGATACAACTTA-3') (SEQ ID No: 2) were used in a PCR, with plasmid template pRW825, to generate a 200bp H6 promoter fragment with the translation initiation codon of the H6 promoter overlapping the RSV F translation initiation codon. Oligonucleotide RW325 contains a *Bam*HI site followed by a sequence which primes 5' of the H6 promoter toward the H6 promoter 3' base pairs. Oligonucleotide primer RW326 contains the 5' base pairs of RSV F followed by a sequence which primes from the H6 translation initiation codon toward the H6 promoter 5' base pairs.

Oligonucleotide RW327 (5'-ATGGAGTTGCTAATCCTC-3') (SEQ ID No: 3) primes from the RSV-F gene translation initiation codon toward the RSV-F 3' end of the RSV F gene coding sequence. Oligonucleotide RW328 (5'-GGGAATACTAATGGGCTTGATATTACTTAATTC-3') (SEQ ID No: 4) primes from the RSV-F gene codon 65 toward the RSV-F 5' base pairs. Template plasmid pSKF7 was used in a PCR with the oligonucleotide primers RW327 and RW328, yielding a 220bp fragment containing the 5' base pairs of RSV F gene. The 3' base pairs of the PCR fragment derived with RW327 and RW328 overlap the 5' base pairs of the following PCR fragment derived with the oligonucleotide primers RW329 and RW330.

The 5' base pairs of oligonucleotide RW329 (5'-TTAAGTAATATCAAGCCCATTAGTATTCCCCTC-3') (SEQ ID No: 5)

contains the reverse complement of RW328 followed by a sequence which primes toward the RSV F gene 3' base pairs. The 5' base pairs of oligonucleotide RW330 (5'-GGTACTTGGAAGCTTTCAGTTACTAAATGCAAT-3') (SEQ ID No: 6) contains a *HindIII* site, followed by a sequence which primes from the RSV-F stop codon toward the RSV F gene 5' base pairs. Oligonucleotide primers RW329 and RW330 were used in a PCR with the template pSKF7. The 5' base pairs of the resultant 330bp RW329/RW330 PCR amplified fragment overlaps the 3' base pairs of the RW327/RW328 PCR product, followed by the 3' base pairs of RSV F gene.

The three overlapping PCR products derived with the primer pairs RW325/RW326, RW327/RW328, and RW329/RW330 were pooled and used as a PCR template with the primers RW325 and RW330. The resultant PCR, amplified with the primers RW325/RW330, fused the three template fragments into one fragment containing the H6 promoted 5' base pairs of the RSV F gene followed by the 3' base pairs of RSV-F gene. Addition of the central RSV-F coding sequences is described below. The RW325/RW330 PCR fragment was digested with *NruI* (within the H6 promoter) and *HindIII* (3' of RSV-F gene) for insertion between the *NruI* and *HindIII* sites of the H6 promoter vector pRW880. The resultant plasmid, pRW884, contains the H6 promoted RSV F gene 5' base pairs followed by the 3' base pairs.

The following RW358/RW330 PCR amplified fragment was used to add the central RSV-F coding sequences to pRW884.

The poxvirus early transcription termination signal TTTTNT (ref. 30) was altered within the RSV-F gene coding sequence, without changing the amino acid coding sequence, with a PCR fragment amplified with the oligonucleotide primers RW358/RW330. The RW358/RW330 PCR fragment was derived from two overlapping PCR fragments in the following manner.

The RSV-F gene central coding sequence contains a poxvirus early transcription termination signal. The TTTTNT sequence was inactivated by base substitution which did not change the amino acid sequence but will prevent early transcriptional termination in a poxvirus vector. Plasmid pRW884 was designed for insertion of the RSV-F central coding sequence, with an inactivated TTTTNT, as a *SpeI*-*NdeI* fragment. Poor efficiency of pRW884 digestion with *NdeI* resulted in a change of strategy from the *SpeI*-*NdeI* fragment to utilization of the following *SpeI*-*HindIII* fragment.

Oligonucleotides RW356 (5'-AGATTTCTTGGTTTCCTGTTAGGTGTTGGATC-3') (SEQ ID No: 7) and RW330 (5'-GGTACTTGGAAGCTTTCAGTTACTAAATGCAAT-3') (SEQ ID No: 6) primed plasmid template pSKF7 for PCR. The 5' base pairs of RW356 contains the poxvirus early transcription termination signal sequence TTTTGT, which has been inactivated by alteration to TTCCTGT, followed by a sequence which primes toward the RSV F gene 3' most base pairs. RW330 contains a *HindIII* site followed by a sequence which primes from the RSV-F gene stop codon toward the RSV F 5' base pairs. The resultant 1.3kbp RW356/RW330 PCR amplified fragment contains the 3' base pairs of RSV F gene. The 5' end of the fragment overlaps the 3' end of the following RW357/RW358 PCR amplified fragment.

Oligonucleotides RW358 (5'-TCTTAGTGCTCTAAGAAC-3') (SEQ ID No: 8) and RW357 (5'-TCCAACACCTAACAGGAAACCAAGAAATCTTC-3') (SEQ ID No: 9) primed plasmid template pSKF7 for PCR, yielding a 300bp fragment. The 5' base pairs of RW357 contains the reverse complement of the altered poxvirus early transcription termination signal followed by a sequence which primes toward the 5' most base pairs of RSV F gene. Oligonucleotide RW358 primes from the 5' base



pairs of RSV F gene toward the 3' base pairs of RSV-F gene.

The two overlapping PCR products amplified with the primer pairs RW356/RW330 or RW357/RW358 were pooled and  
5 used as a PCR template with the primers RW358 and RW330. The resultant 1.6kbp RW358/RW330 PCR amplified fragment, containing the 3' base pairs of RSV F gene and an inactivated poxvirus early transcription termination signal, was digested with *SpeI* and *HindIII*, yielding a  
10 1.56kbp fragment. The 1.56kbp *SpeI/HindIII* digested RW358/RW330 PCR amplified fragment was inserted between the *SpeI* and *HindIII* sites of pRW884. The resultant plasmid pRW887 contains the H6 promoted RSV-F gene open reading frame flanked by *NotI* restriction sites.

15 Plasmid pC6L was used as a vector for the H6 promoted RSV-F gene from pRW887. Plasmid pC6L was constructed by deleting the C6 ORF and replacing it with multiple cloning sites flanked by transcriptional and translational termination signals in the following  
20 manner. A 380 bp PCR fragment was amplified from genomic ALVAC DNA using oligonucleotide primers C6A1 (5'-ATCATCGAGCTCGCGGCCGCCTATCAAAAGTCTTAATGAGTT-3') (SEQ ID No: 10) and C6B1 (5'-GAATTCCTCGAGCTGCAGCCCGGGTTTTATAGCTAATTAGTCATTTTTTCGTAAG  
25 TAAGTATTTTTATTAA-3') (SEQ ID No: 11). A 1155 bp PCR fragment was amplified from genomic ALVAC DNA using oligonucleotide primers C6C1 (5'-CCCGGGCTGCAGCTCGAGGAATTCTTTTTATTGATTAAGTCAATGAGTATATATAATTGAAAAGTAA-3') (SEQ ID No: 12) and C6D1 (5'-  
30 GATGATGGTACCTTCATAAATACAAGTTTGATTAACTTAAGTTG-3') (SEQ ID No: 13). The 380 bp and 1155 bp fragments were fused by adding them together as a template and amplifying a 1613 bp PCR fragment using oligonucleotide primers C6A1 and C6D1. This fragment was digested with *SacI/KpnI* and  
35 ligated into pBluescript SK+ digested with *SacI/KpnI*. The resulting plasmid, pC6L was confirmed by DNA

sequence analysis. It consists of 370 bp of ALVAC DNA upstream of C6, vaccinia early termination signal, translation stop codons in six reading frames, multiple cloning sites containing *SmaI*, *PstI*, *XhoI* and *EcoRI* sites, vaccinia early termination signal, translation stop codons in six reading frames and 1156 bp of downstream ALVAC sequence.

The 1.9kbp pRW887 *NotI* fragment, containing the H6 promoted RSV-F gene expression cassette, was blunt ended with Klenow DNA polymerase in the presence of 20mM dNTPs and inserted into the *SmaI* site of the ALVAC C6 donor plasmid pC6L. The resultant plasmid pRW927 contains the H6 promoted RSV-F open reading frame in a C6 donor plasmid. Plasmid pRW927 was used in *in vitro* recombination experiments with ALVAC as the rescuing virus to yield vCP181.

#### Example 2

This Example describes the construction of the NYVAC recombinant containing the RSV-F gene.

The H6 promoted RSV-F gene expression cassette was moved into the NYVAC donor plasmid pSD544. Plasmid pSD544 was constructed in the following manner. pSD456 is a subclone of Copenhagen vaccinia DNA containing the HA gene (ref. 31) and surrounding regions. pSD456 was used as a template in PCR for synthesis of left and right vaccinia arms flanking the A56R ORF. The left arm was synthesized using oligonucleotides MPSYN279 (5'-CCCCCGAATTCGTCGACGATTGTTTCATGATGGCAAGAT-3') (SEQ ID No: 14) and MPSYN280 (5'-CCCGGGGATCCCTCGAGGGTACCAAGCTTAATTAATTAATATTAGTATAAAAAGTGATTTATTTTT-3') (SEQ ID No: 15). The right arm was synthesized using oligonucleotides MPSYN281 (5'-AAGCTTGGTACCCTCGAGGGATCCCCGGGTAGCTAGCTAATTTTTCTTTTACGTTATA TATGTAATAAACGTTTC-3') (SEQ ID No: 16) and MPSYN312 (5'-TTTTTTCTGCAGGTAAGTATTTTAAACTTCTAACACC-3') (SEQ ID

No: 17). The purified PCR fragments for the left and right arms were combined in a further PCR reaction. The resulting product was digested with *EcoRI/HindIII*. The resulting 0.9 kb fragment was cloned into *EcoRI/HindIII* 5 digested pUC8 resulting in plasmid pSD544.

The previously described 1.9kbp pRW887 *NotI* fragment, containing the H6 promoted RSV F gene expression cassette, was blunt ended with Klenow DNA polymerase in the presence of 20mM dNTPs and inserted 10 into the *SmaI* site of the vaccinia virus HA donor plasmid pSD544. The resultant plasmid pRW891 contains the H6 promoted RSV-F gene open reading frame in an HA donor plasmid. Plasmid pRW891 was used in *in vitro* recombination experiments with NYVAC as the rescuing 15 virus to yield vP1000.

### Example 3

This Example describes the expression analysis of vCP181 (ALVAC-F recombinant virus) and vP1000 (NYVAC-F 20 recombinant virus).

Immunoprecipitation analysis was performed to assay RSV-F expression in vCP181 (ALVAC-F) and vP1000 (NYVAC-F) infected cells. Authentic RSV-F is expressed as an  $F_0$  (68-70kDa) precursor which is cleaved, yielding the 25 products  $F_1$ (46kDa) and  $F_2$  (22kDa). Polypeptide species corresponding to proteins with molecular weights consistent with  $F_0$ ,  $F_1$ , and  $F_2$  in lysates derived from vCP181 and vP1000 infected cells were detected using rabbit anti-RSV antiserum.

30 More specifically, HeLa, MRC-5, or CEF cells were labelled with 20-50 $\mu$ Ci/ml  $^{35}$ S methionine (NEN, Boston, MA) and infected with recombinant or control virus at an MOI of 10. Rabbit anti-RSV F antiserum (Pasteur Merieux, 46-3-S9 du 30.08.89) was used in immunoprecipitations at 35 dilutions of 1:10 to 1:100. Negligible reactivity was obtained, at molecular weights consistent with  $F_0$ ,  $F_1$ ,

and F<sub>2</sub> , from cells infected with the control viruses ALVAC or NYVAC. Both vCP181 (ALVAC-F) and vP1000 (NYVAC-F) were positive for RSV-F expression. The vCP181 or vP1000 infected cells yielded antigens of the appropriate sizes for RSV-F<sub>0</sub>, F<sub>1</sub>, and F<sub>2</sub>.

#### Example 4

This Example illustrates the process of purifying RSV proteins.

10 African Green monkey kidney cells (VERO) at a concentration of 10<sup>5</sup> cells/mL were added to 60L of CMRL 1969 medium, pH 7.2 in a 150L bioreactor containing 360 g of Cytodex-1 microcarrier beads and stirred for 2 hours. An additional 60L of CMRL 1969 was added to give  
15 a total volume of 120L. Fetal bovine serum was added to achieve a final concentration of 3.5%. Glucose was added to a final concentration of 3 g/L and L-glutamine was added to a final concentration of 0.6 g/L. Dissolved oxygen (40%), pH (7.2), agitation (36 rpm), and  
20 temperature (37°C) were controlled. Cell growth, glucose, lactate, and glutamine levels were monitored. At day 4, the culture medium was drained from the fermenter and 100L of E199 media (without fetal bovine serum) was added and stirred for 10 minutes. The  
25 fermenter was drained and filled again with 120 L of E199. The RSV inoculum was added at a multiplicity of infection (M.O.I.) of 0.001 and the culture was then maintained for 3 days before one-third to one-half of the media was drained and replaced with fresh media. On  
30 day 6 post-infection, the stirring was stopped and the beads allowed to settle. The viral culture fluid was drained and filtered through a 20 µm filter followed by a 3 µm filter prior to further processing. The clarified viral harvest was concentrated 75-150 fold  
35 using tangential flow ultrafiltration with 300 NMWL membranes and diafiltered with phosphate buffered saline

containing 10% glycerol. The viral concentrate was stored frozen at  $-70^{\circ}\text{C}$  prior to further purification. A solution of 50% polyethylene glycol-8000 was added to an aliquot of virus concentrate to give a final concentration of 6%. After stirring at room temperature for one hour, the mixture was centrifuged at 15,000 RPM for 30 min. in a Sorvall SS-34 rotor at  $4^{\circ}\text{C}$ . In some instances the viral pellet was suspended in 1 mM sodium phosphate, pH 6.8, 2 M urea, 0.15 M NaCl, stirred for 1 hour at room temperature, and then recentrifuged at 15,000 RPM for 30 min. in a Sorvall SS-34 rotor at  $4^{\circ}\text{C}$ . The viral pellet was then suspended in 1mM sodium phosphate, pH 6.8, 50 mM NaCl, 1% Triton X-100 and stirred for 30 min. at room temperature. The insoluble virus core was removed by centrifugation at 15,000 RPM for 30 min. in a Sorval SS-34 rotor at  $4^{\circ}\text{C}$ . The soluble protein supernatant was applied to a column of ceramic hydroxyapatite (type II, Bio-Rad Laboratories) and the column was then washed with five column volumes of 1 mM sodium phosphate, pH 6.8, 50 mM NaCl, 0.02% Triton X-100. The RSV proteins were obtained by eluting the column with 10 column volumes of 1 mM sodium phosphate, pH 6.8, 400 mM NaCl, 0.02% Triton X-100.

The RSV proteins were analyzed by SDS-PAGE using 12.5% acrylamide gels and by immunoblotting. Samples were electrophoresed in the presence or absence of the reducing agent 2-mercaptoethanol. Gels were stained with silver stain to detect the viral proteins (Figures 1a and 1b). Immunoblots of replicate gels were prepared and probed with a mouse monoclonal antibody (mAb 5353C75) to F glycoprotein (Figures 2a and 3a), or a mouse monoclonal antibody (mAb 131-2G), to G glycoprotein (Figures 2b and 3b) or guinea pig anti-serum (gp178) against an RSV M peptide (peptide sequence: LKSKNMLTTVKDLTMKTLNPTHDIIALCEFEN - SEQ ID No: 20) (Figures 2c and 3c), or goat anti-serum (Virostat

#0605) against whole RSV (Figures 2d and 3d).  
Densitometric analysis of the silver-stained gel of RSV subunit preparation electrophoresed under reducing conditions indicated a compositional distribution as follows:

G glycoprotein (95 kDa form) = 10 %

F<sub>1</sub> glycoprotein (48 kDa) = 30 %

M protein (31 kDa) = 23 %

F<sub>2</sub> glycoprotein (23 kDa) = 19 %

10 The F glycoprotein migrates under non-reducing conditions as a heterodimer of approximately 70 kDa (F<sub>0</sub>) as well as higher oligomeric forms (dimers and trimers) (Figure 3a).

#### 15 Example 5

This Example describes the immunization of animals by priming with the ALVAC-F recombinant virus and boosting with RSV proteins.

Pathogen-free BALB/c mice (approximately 8 weeks  
20 old; 17 animals per group) were immunized according to the immunization protocol outlined in Table 1.

Animals were bled 4 weeks after the primary inoculation and boosted with the vaccine formulation outlined in Table 1. Serum samples were also taken 4  
25 weeks after the booster dose. The anti-RSV F antibody titres in the sera of mice that were immunized according to the protocol outlined in Table 1 are summarized in Figure 6.

With the exception of the control animals, the sera  
30 of mice immunized with the various RSV formulations contained had anti-F IgG antibodies. The sera from animals that were primed with the ALVAC-F recombinant virus of Example 1 and boosted with either the ALVAC-F recombinant virus or the subunit preparation of Example  
35 5 had anti-F IgG1/IgG2a ratios of approximately 1:1. This is in contrast to the anti-RSV F IgG1/IgG2a ratios

obtained in mice that were primed and boosted with the alum-adsjuvanted FI-RSV (8:1) or subunit vaccine (11:1). These results indicate that priming animals with the ALVAC-F recombinant virus results in a balanced anti-RSV F IgG1/IgG2a response and sets the stage for a Th-1 type response.

As shown in Figure 7, the sera of mice that were primed and boosted with the various RSV preparations outlined in Table 1, all had significant levels of RSV-specific neutralizing antibodies. The RSV-specific neutralizing antibody titers ( $13 \log_2$ ) were significantly higher in animals that were primed with the ALVAC-F recombinant and boosted with the subunit preparation than in mice that were primed and boosted with the ALVAC-F recombinant virus (neutralizing antibody titre  $8.8 \log_2$ ). Thus, priming animals with the ALVAC-F recombinant virus not only appears sets the stage for a Th-1 type response but also results in the induction of high titres of RSV-specific neutralizing antibodies after boosting with the alum-adsjuvanted RSV subunit vaccine.

#### Example 6

This Example describes the determination of Anti-F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV-F protein diluted in 0.05M carbonate-bicarbonate buffer, pH9.6. Wells were blocked for non-specific binding by adding 0.1% BSA in PBS for 30 min. at room temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After one hour incubation at room temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labelled conjugate was

added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab')<sub>2</sub> goat anti-mouse IgG (H+L specific)-HRP from Jackson Immuno Research Laboratory Inc., Baltimore, Maryland. Sheep  
5 anti-mouse IgG1-HRP from Serotec, Toronto, Ontario was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories, San Francisco, California was used in the IgG2a assay. Following one hour incubation at room temperature, the plates were washed five times with  
10 washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken  
15 as the reciprocal of the last dilution at which the OD was approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

20

#### Example 7

This Example describes the generation of RSV-specific cytotoxic T-cells in mice primed with live recombinant poxvirus and boosted with RSV proteins.

25 Splens from two BALB/c mice from each group that were immunized according to the immunization protocol outlined in Table 1 were removed three weeks after the booster dose. Single cell suspensions were prepared and incubated at  $2.5 \times 10^7$  cells in RPMI 1640 plus 10% fetal  
30 bovine serum (FBS). Gamma-irradiated (3,000 rads) syngeneic spleen cells were infected with RSV at an MOI of 1 for 2 hours. The cells were washed twice to remove free virus and  $2.5 \times 10^7$  virus infected feeder cells were added to the  $2.5 \times 10^7$  spleen cells in a final volume of  
35 10 mL of complete medium. CTL activity was tested 5 to 6 days following re-stimulation. On the day of the



assay, effector cells were washed twice with fresh medium and viable cell counts were determined by the Trypan blue dye exclusion method. BC cells ( $2 \times 10^6$  cells), a BALB/c fibroblast cell line, as well as BCH4 cells ( $2 \times 10^6$  cells), a BALB/c fibroblast T cell line persistently infected with RSV, were pulsed with 200  $\mu$ Ci of Sodium  $^{51}$ chromate (Dupont) for 90 min. The targets were washed three times with medium to remove free  $^{51}$ chromium. Viable cell counts of the target cells were determined and target cell suspensions were prepared at  $2 \times 10^4$  cells/mL. Washed responder T-cells (in 100  $\mu$ L) were incubated with  $2 \times 10^3$  target cells (in 100  $\mu$ L) at varying Effector:Target cell ratios in triplicates in a 96-well V-bottomed tissue-culture plates for 4 hours at 37°C with 6% CO<sub>2</sub>. Spontaneous and total release of  $^{51}$ chromium were determined by incubating target cells with either medium or 2.5% Triton X-100 in the absence of responder lymphocytes, respectively. Six replicates of each were prepared. After 4 hours, plates were centrifuged at 200 x g for 2 min and 100  $\mu$ L of supernatant were removed from each well to determine the amount of  $^{51}$ chromium released. Percentage specific  $^{51}$ chromium release was calculated as (Experimental Release - Spontaneous Release)/(Total Release - Spontaneous Release) x 100. The Spontaneous Release of  $^{51}$ chromium in the absence of effector cells was found to be between 10 to 15% in these studies.

As shown in Figure 8, CTLs generated from mice that were primed with ALVAC-F recombinant virus and boosted with the subunit vaccine ( $\square$ ), or primed and boosted with the ALVAC-F recombinant virus ( $\Delta$ ) or live mouse adapted virus ( $\blacklozenge$ ) lysed BCH4 cells (persistently infected with RSV) at all effector cell dilutions, when compared to the lysis of BC (control) cells. CTL activity was not observed in animals that were primed

and boosted with either the alum-adjuvanted RSV subunit vaccine or F-RSV. Thus, priming animals with the ALVAC-F vector and boosting them with either the ALVAC-F vector or alum-adjuvanted RSV subunit vaccine induced 5 significant levels of CTL activity.

Example 8

This Example describes the protection of mice primed with ALVAC-F recombinant virus and boosted with RSV proteins.

10 Immunized mice were challenged intranasally with mouse-adapted RSV, A2 subtype. Lungs were aseptically removed about four days later, weighed and homogenized. The number of pfu in the lung homogenate was determined as described by Prince et al. (ref. 32) using VERO  
15 cells. The results are shown in Table 2 below.

In contrast to the placebo control animals (groups 6, 7, 8), the lower respiratory tract of mice that were primed with the ALVAC-F recombinant virus and boosted with the alum-adjuvanted RSV subunit preparation was  
20 completely protected against live virus challenge. Complete protection was also observed in animals that were immunized with two 1 µg doses of the alum-adjuvanted subunit vaccine or given live mouse-adapted RSV.

25 Boosting ALVAC-F primed animals with the alum-adjuvanted subunit preparation resulted in a more durable protective response. It was observed that 3 out of 6 animals that were primed and boosted with the ALVAC-F recombinant virus had low, yet detectable levels  
30 of RSV in their lungs. In contrast, virus was not detected in the lungs of mice that were primed with the ALVAC-F recombinant virus and boosted with the subunit preparation.

SUMMARY OF DISCLOSURE

In summary of this disclosure, the present invention provides a novel immunization strategy to induce protection against paramyxoviridae virus disease, especially RSV, which is safe and effective. Modifications are possible within the scope of this invention.

Table 1: Immunization protocol

GROUP	PRIME	ROUTE OF INOCULATION	BOOST	ROUTE OF INOCULATION
1	ALVAC-F <sup>1</sup>	Intramuscular	Subunit Preparation <sup>2</sup> + alum	Intramuscular
2	ALVAC-F <sup>1</sup>	Intramuscular	ALVAC-F	Intramuscular
3	Subunit preparation + alum	Intramuscular	Subunit vaccine + alum	Intramuscular
4	Live RSV <sup>3</sup>	Intranasal	Live RSV	Intranasal
5	FI-RSV <sup>4</sup> + alum	Intramuscular	FI-RSV + alum	Intramuscular
6	Irrelevant ALVAC	Intramuscular	Irrelevant ALVAC	Intramuscular
7	PBS + alum	Intramuscular	PBS + alum	Intramuscular
8	EMEM +5% FBS +5% glycerol	Intranasal	EMEM +5% FBS +5% glycerol	Intranasal

Mice were inoculated with:

- <sup>1</sup>  $5 \times 10^7$  pfu of the ALVAC-F recombinant virus that was prepared according to the procedure outlined in Example 1
- <sup>2</sup> 1  $\mu$ g of RSV subunit vaccine (Example 4) adsorbed to alum (1.5 mg/dose)
- <sup>3</sup>  $2.5 \times 10^5$  pfu of mouse-adapted A2 virus
- <sup>4</sup> 100  $\mu$ l of 100 X formalin-inactivated (FI) RSV vaccine adsorbed to alum.

Table 2: Protective ability of the various RSV formulations in BALB/c mice

Group #	Antigen Formulation		Mean virus lung titre (log <sub>10</sub> /g $\pm$ s.d.)
	Prime	Boost	
1	ALVAC-F	Subunit preparation + alum	$\leq 2.2 \pm 0$
2	ALVAC-F	ALVAC-F	$2.4 \pm 0.3$
3	Subunit preparation + alum	Subunit preparation + alum	$\leq 2.2 \pm 0$
4	Live RSV	Live RSV	$\leq 2.2 \pm 0$
5	FI-RSV	FI-RSV	$2.2 \pm 0$
6	Irrelevant ALVAC	Irrelevant ALVAC	$5.2 \pm 0.3$
7	PBS + alum	PBS + alum	$5.1 \pm 0.2$
8	EMEM +5% FBS +5% glycerol	EMEM +5% +5% glycerol	$5.2 \pm 0.4$

REFERENCES:

1. Glezen, W.P., Paredes, A. Allison, J.E., Taber, L.H. and Frank, A.L. (1981). J. Pediatr. 98, 708-715.
2. Chanock, R.M., Parrot, R.H., Connors, M., Collins, P.L. and Murphy, B.R. (1992) Pediatrics 90, 137-142.
3. Martin, A. J., Gardiner, P.S. and McQuillin, J. (1978). Lancet ii, 1035-1038.
4. Robbins, A., and Freeman, P. (1988) Sci. Am. 259, 126-133.
5. Glezen, W.P., Taber, L.H., Frank, A.L. and Kasel, J.A. (1986) Am. J. Dis. Child. 140, 143-146.
6. Katz, S.L. New vaccine development establishing priorities. Vol. 1. Washington: National Academic Press. (1985) pp. 397-409.
7. Wertz, G.W., Sullender, W.M. (1992) Biotech. 20, 151-176.
8. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, i.W., Minamitani, M. and Meiklejohn, G. (1969) Am. J. Epidemiol. 89 (4), 435-448.
9. McIntosh, K. and Chanock, R.M. (1990) in Fields Virology (Fields, B.M., and Knipe, D.M. eds.) pp. 1045-1075, Raven Press, Ltd., New York.
10. Cherrie, A.H., Anderson K, Wertz GW, and Openshaw PJM, 1992, J. Virology, 66: 2102-2110
11. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) Am. J. Epidemiol. 89 (4), 449-463.
12. Kapikian, A.Z., Mitchell, R.H., Chanock, R.M., Shvedoff, R.A. and Stewart, C.E. (1969) Am. J. Epidemiol. 89 (4), 405-421.
13. Connors, M., Collins, P.L., Firestone, C.Y., Sotnikov, A.V., Waitze, A., Davis, A.R., Hung, P.P., Chanock, R.M., Murphy, b. (1992) Vaccine, 10, 475-484.
14. Walsh, E.E., Hall, C.B., Briselli, M., Brandiss, M.W. and Schlesinger, J.J. (1987) J. Infect. Dis. 155 (6), 1198-1204.

15. Connors M, Kulkarni, CY, Firestone KL, Holmes KL, Morse III HC, Sotnikov AV, and Murphy BR, (1992). J. Virol. 66: 7444-7451.
16. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse III HC, and Murphy BR, (1994) J. Virol. 68: 5321-5325.
17. Waris, ME, Tsou C., Erdman DD, Zaki SR and Anderson., (1996), J. Virol. 70: 2852-2860.
18. Fenner, F., Henderson, D.A., Arita, I., Jezek, J., Ladnyi, I.D. (1988) Smallpox and its Eradication. Geneva. World Health Organization.
19. Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.-C., Cox, W.I., Davis, S.W., VanderHoeven, J., Maignier, B., Riviere, M., Languet, B., Paoletti, E. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
20. Konishi, E., Pincus, S., Paoletti, E., Laegried, W.W., Shope, R.E., Mason, P.W. (1992) A highly attenuated host-range restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 190, 454-458.
21. Taylor, J., Weinberg, R., Kawaoka, Y., Webster, R., Paoletti, E. (1988a) Protective immunity against avian influenza induced by a fowlpoxvirus recombinant. Vaccine 6, 504-508.
22. Taylor, J., Weinberg, R., Languet, B., Desmettre, Ph., Paoletti, E. (1988b) Recombinant fowlpoxvirus inducing protective immunity in non-avian species. Vaccine 6, 497-503.
23. Taylor, J., Trimarchi, C., Weinberg, R., Languet, B., Guillemin, F., Desmettre, Ph., Paoletti, E. (1991) Efficacy studies on a canarypox-rabies recombinant. Vaccine 9, 190-193.
24. Taylor, J., Weinberg, R., Tartaglia, J., Richardson, C., Alkatib, G., Briedis, D., Appel, M., Norton, E., Paoletti, E. (1992) Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187, 321-328.
25. Tartaglia, J., Taylor, J., Cox, W.I., Audonnet, J.-C., Perkus, M.E., Raedelli, A., de Giuli Morghen,

- C., Meignier, B., Riviere, M., Weinhold, K., Paoletti, E. (1993) Novel poxvirus strains as research tools and vaccine vectors. In AIDS Research Reviews (W.C. Koff, F. Wong-Staal, and R.C. Kennedy, eds.), vol. 3, Marcel Dekker, New York, 361-378.
26. Cadoz, M., Strady, A., Meignier, B., Taylor, J., Taryaglia, J., Paoletti, E., Plotkin, S. (1992) Immunization with canarypox virus expressing rabies glycoproteins. *Lancet* 339, 1429-1432.
27. Pialoux, G., Excler, J.-L., Riviere, Y., Gonzalez-Canali, G., Feuillie, V., Coulaud, P., Gluckman, J.-C., Matthews, T.J., Meignier, B., Kieny, M.-P., Gonnet, P., Diaz, I., Meric, C., Paoletti, E., Tartaglia, J., Salomon, H., Plotkin, S. (1995) A primeboost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein gp160 (MN) followed by a recombinant glycoprotein 160 (MN/Lai). *AIDS Res. Hum. Retrovir.* 11, 373-381.
28. Mullis, K., Ferre, F., and Gibbs, R. (1994) *The Polymerase Chain Reaction*. Boston: Birkhauser press.
29. Perkus, M., Limbach, K. and Paoletti, E. (1989) Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. *J. Virol.* 63: 3829-3836.
30. Yuen, L. and Moss, B. (1987) *PNAS* 84: 6417-6421.
31. Goebel, S., Johnson, G., Perkus, M., Davis, S., Winslow, J., and Paoletti, E. (1990) The complete DNA sequence of vaccinia virus, *Virology* 179: 247-266.
32. Prince, G.A. et al. 1978, *Am J. Pathol.* 93: 771-790.
33. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
34. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
35. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
36. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke



- Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
37. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
38. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
39. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
40. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
41. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
42. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
43. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.
44. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) *J. Infect. Dis.* 157 (4), 648-654.
45. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) *J. Infect. Dis.* 162, 746-749.
46. Ray, R., Glaze, B.J. and Compans, R.W. (1988) *J. Virol.* 62 (3), 783-787.
47. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) *Vaccine* 10 (6), 412-420.
48. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) *Vaccine* 9, 505-511.
49. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. *J. Virol.* 1984; 52:828-32.
50. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed,

- P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) J. Gen. Virol. 74, 459-469.
51. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) J. Gen. Virol. 74, 471-477.
52. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) Vir. Res. 24, 21-33.
53. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) Vaccine 9, 659-667.

CLAIMS

What we claim is:

1. A method of immunizing a host against disease caused by infection by a paramyxoviridae, which comprises:

initially administering to the host an immunoeffective amount of a recombinant virus vector expressing at least one paramyxoviridae virus protein or immunogenic fragment thereof; and

subsequently administering to the host an immunoeffective amount of at least one purified paramyxoviridae virus protein or immunogenic fragment thereof of the same at least one paramyxoviridae virus protein as in the initial administration, to achieve a paramyxovirus specific protective immune response in the host.

2. The method of claim 1 wherein said immune response in the host includes the production of virus specific neutralizing antibodies and/or virus specific cytotoxic T-cell responses.

3. The method of claim 2 wherein said paramyxovirus is selected from the group consisting of respiratory syncytial virus (RSV) and parainfluenza virus (PIV).

4. The method of claim 3 wherein said recombinant virus is a recombinant pox virus.

5. The method of claim 3 wherein said recombinant virus expresses at least one of the fusion (F), attachment (G) and matrix (M) proteins of RSV or an immunogenic fragment thereof.

6. The method of claim 3 wherein said at least one purified RSV protein or immunogenic fragment thereof is selected from the group consisting of the fusion (F), attachment (G) and matrix (M) proteins of RSV or immunogenic fragments thereof.


7. The method of claim 6 wherein said recombinant virus is a recombinant pox virus.

8. The method of claim 6 wherein said recombinant virus expresses at least one of the fusion (F), attachment (G) and matrix (M) proteins of RSV or an immunogenic fragment thereof.
9. The method of claim 1 wherein the at least one purified protein or immunogenic fragment thereof is administered with an adjuvant.
10. The method of claim 9 wherein the adjuvant is alum.
11. A recombinant poxvirus containing therein a nucleic acid sequence encoding a paramyxovirus protein or immunogenic fragment thereof in a non-essential region of the recombinant virus genome.
12. The recombinant poxvirus of claim 11 wherein said poxvirus is a vaccinia virus.
13. The recombinant poxvirus of claim 12 wherein said recombinant virus has non-essential virus-encoded genetic functions inactivated therein.
14. The recombinant poxvirus of claim 13 wherein said nucleic acid sequence encodes the fusion (F) glycoprotein of respiratory syncytial virus (RSV).
15. The recombinant poxvirus of claim 14 which is recombinant virus vP1000 (NYVAC-F) (ATCC No. VR-2540).
16. The recombinant poxvirus of claim 11 wherein said poxvirus is an avipox virus.
17. The recombinant poxvirus of claim 16 wherein said nucleic acid sequence ~~encodes the~~ fusion (F) glycoprotein of respiratory syncytial virus (RSV).
18. The recombinant poxvirus of claim 17 which is recombinant virus vCP181 (ALVAC-F) (ATCC No. VR-2541).
19. A recombinant poxvirus containing therein a nucleic acid sequence encoding a paramyxovirus protein or immunogenic fragment thereof in a non-essential region of the recombinant virus genome when used as a medicine.
20. The use of a recombinant poxvirus containing therein a nucleic acid sequence encoding a paramyxovirus protein or immunogenic fragment thereof in a non-

essential region of the recombinant virus genome in the manufacture of a medicament for an immunizing host against disease caused by infection by a paramyxoviridae.

1/13


Figure 1 - SDS-PAGE Analysis of RSV Subunit (silver stain)



Lane 1 = Molecular Weight Standards  
Lane 2 = RSV Subunit

2/13


Figure 2 - Western Blot Analysis of RSV Subunit  
Reduced



Lane 1 = Molecular Weight Standards  
Lane 2 = RSV Subunit

3/13

Figure 3 - Western Blot Analysis of RSV Subunit  
Non-Reduced



Lane 1 = Molecular Weight Standards  
Lane 2 = RSV Subunit



4/13

## FIG.4

Nucleotide sequence of the vCP181 (ALVAC-F) H6 promoted RSV- F insertion and flanking sequences. The H6 promoter begins at position 202. RSV-F starts at position 326 and ends at position 2048.

```

1  ATACATAATGGATTTTGTGTTATCATCAGTTATATTTAACATAAGTACATAAAAGTATTA
61  AATAAAAA TACTTACTTACGAAAAAATGACTAATTAGCTATAAAACCCGGCCGCTTTT
121 ATTAAATTAATTAACCCGGTTAATTAATTAGTTATTAGACAAGGTGAAACGAACTATT
181 TGAGCTTAATTAATTAGAGCTTCTTTATTCTATACTTAAAGTGAAATAAATACAAA
241 GGTTCCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCATAAATTAATTTCATTATCG
301 CGATATCCGTTAAGTTTGTAATCGTAATGGAGTTGCTAATCCTCAAAGCAAATGCAATTAC
361 CACAATCCTCGCTGCAGTCACATTTTGCTTTTGCTTAGTCAAAACATCACTGAAGAATT
421 TTATCAATCAACATGCAGTGCAGTTAGCAAGGCTATCTTAGTGCTCTAAGAACTGGTTG
481 GTATACTAGTGTATAACTATAGAAATTAAGTAATATCAAGGAAATAAGTGTAATGGAAC
541 AGATGCTAAGGTAAATTGATAAAACAAGAATTAGATAAATATAAAATGCTGTACAGA
601 ATTGCAGTTGCTCATGCAAAAGCACATCAGCAGCAACAAATCGAGCCAGAAAGAACTACC
661 AAGGTTTATGAATTATACACTCAACAAATACCAAAACCAATGTAAACATTAAAGCAAGAA
721 AAGGAAAAGAAGATTCTTGGTTTGTGTTAGGTGTTGGATCTGCAATCGCCAGTGGCAT
781 TGCTGTATCTAAGGTCCTGCACTTAGAAGGAGAAAGTGAACAAGATCAAAAGTGCTCTACT
841 ATCCACAACAAGGCCGTAGTCAGCTTATCAATGGAGTTAGTGTCTTAACCCAGCAAAGT
901 GTTAGACCTCAAAAACCTATATAGATAAACAAATTGTTACCTATTGTGAATAAGCAAAGCTG
961 CAGAAATATCAAAATATAGAAACTGTGATAGAGTTCCAAACAAAGAACACAGACTACTAGA
1021 GATTACCAGGGAATTTAGTGTAAATGCAGGTGTAACCTACACCTGTAAAGCACTTACATGTT
1081 AACTAATAGTGAATTATTGTCAATTAATCAATGATATGCCTATAACAAATGATCAGAAAAA
1141 GTTAATGTCCAAACAATGTTCAAAATAGTTAGACAGCAAGTTACTCTATCATGTCCATAAT
1201 AAAAGAGGAAGTCTTAGCATATGTAGTACAATTACCACTATATGGTGTGATAGATACACC

```

## FIG.4 con't

1261 TTGTTGGAAATTACACACATCCCCCTCTATGTACACCAACACAAAGAAGGGTCAAACAT  
1321 CTGTTTACAAAGAACTGACAGAGGATGGTACTGTGACAAATGCAGGATCAGTATCTTTCTT  
1381 CCCACAAGCTGAACATGTAAAGTTCAATCGAATCGAGTATTTTGTGACACAAATGAACAG  
1441 TTTAACATTACCAAGTGAAAGTAAATCTCTGCAATGTTGACATATTCAATCCCAATATGA  
1501 TTGTAAAATTATGACTTCAAAAACAGATGTAGCAGCTCCGTTATCACATCTCTAGGAGC  
1561 CATTTGTGTCATGCTATGGCAAACTAAATGTACAGCATCCAAATAAAATCGTGGAAATCAT  
1621 AAAGACATTTTCTAACGGGTGTGATTATGTATCAAAATAAAGGGTGGACACTGTGTCTGT  
1681 AGGTAACACATTATATTATGTAAATAAGCAAGAGGCAAAAGTCTCTATGTAAAAGGTGA  
1741 ACCAATAATAATTTCTATGACCCATTAGTATTTCCCTCTGATGAATTTGATGCATCAAT  
1801 ATCTCAAGTCAATGAGAAGATTAAACCAGAGTTAGCATTTATTCGTAAATCCGATGAATT  
1861 ATTACATCATGTAAATGCTGGTAAATCAACCACAAATATCATGATAACTACTATAATTAT  
1921 AGTGATTATAGTAAATATTGTTATCATTAATTGCTGTTGGACTGCTCCTATACTGTAAAGGC  
1981 CAGAAGCACACCAGTCACACTAAGCAAGGATCAACTGAGTGGTATAAATAATATTGCATT  
2041 TAGTAACTGAAAGCTTCTAGCTAGCTAAATTTTATAGCGGCCGGGCTGCAGCTCGAGGAA  
2101 TTCCTTTTATTGATTAACTAGTCAAAATGAGTATATATAATTGAAAAGTAAATATAAAT  
2161 CATATAATAATGAAAC

5/13

6/13

## FIG.5

Nucleotide sequence of the vP1000 (NYVAC-F) H6 promoted RSV-F insertion and flanking sequences. The H6 promoter begins at position 575. RSV-F starts at position 699 and ends at position 2421.

```
1  GTCGACGATTGTTTCATGATGGCAAGATTTATATATCTGGAGGTTACAACAATAGTAGTGT
61  AGTTAATGTAATATCGAATCTAGTCCTTAGCTATAATCCGATATATGATGAATGGACCAA
121 ATTATCATCATTAACATTCCTAGAAATTAATCCCGCTCTATGGTCAGCGCATAAATAATT
181 ATATGTAGGAGGAGGAATATCTGATGATGTTTCGAACTAATACATCTGAAACATACGATAA
241 AGAAAAAGATTGTTGGACAATTGGATAATGGTCACGTGTACCACGCAATTATATATGTA
301 TAAATGCGAACCGATTAAACATAAATATCCATTGGAAAAACACACGACGATGATTT
361 TCTAAAGTATTTGGAAAGTTTATAGGTAGTTGATAGAACAAATACATAATTTTGTAAA
421 AATAAATCACTTTTTATACTAATAATTTAATTAAAGCTTGGTACCCCTCGAGGGATCCC
481 CCGGCCGCTTTTATTAATTAAACCCGGTTAATTAAATTAGTTATTAGACAAAGGTGA
541 AACGAAACTATTGTAGCTTAAATTAATTAGAGCTTCTTTATTCTATACTTAAAGTGA
601 AAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAATCATAAAT
661 TATTTCAATTATCGCGATATCCGTTAAGTTTGTATCGTAATGGAGTTGCTAATCCTCAAAG
721 CAAATGCAATTACCACAAATCCTCGCTGCAGTCACATTTTGCCTTCTAGTCAAAACA
781 TCACTGAAGAAATTTTATCAATCAACATGCAGTGCAGTTAGCAAGGCTATCTTAGTGCTC
841 TAAGAACTGGTTGGTATACTAGTGTATAACTATAGAAATTAGTAATATCAAGGAAATA
901 AGTGTAATGGAACAGATGCTAAGGTAAAAATTGATAAAACAAGAAATTAGATAAATAAAA
961 ATGCTGTAAACAGAAATTGCAGTTGCTCATGCAAGCACATCAGCAGCAACAATCGAGCCA
1021 GAAGAGAACTACCAAGGTTTATGAATTATACACTCAACAATACCAAAAAACCAATGTAA
1081 CATTAAAGCAAGAAAAAGGAAGGAAGATTCTTGGTTTTTGTAGGTGTTGGATCTGCAA
```

7/13

## FIG.5 con't

1141 TCGCCAGTGGCA TTGGTGTA TCTAAGGTCCTGCACTTAGAAGGAGAA GTGAACAAGATCA  
1201 AAAGTGCTCTACTATGCACAAACAAGGCCGTAGTCAGCTTATCAAA TGAGTTAGTGCT  
1261 TAACCAGCAAAGTGT TAGACCTCAAAACTATATAGATAAACAATTGTTACCTATTGTGA  
1321 ATAAGCAAAGCTGCAGAAATATCAAAATATAGAACTGTGATAGAGTTCCAAACAAGAACA  
1381 ACAGACTACTAGAGATTACCAGGGAATTTAGTGTTAATGCAGGTGTAAC TACACCTGTAA  
1441 GCACTTACATGTTAAGTAA TAGTGAATTATTGTCA TTAATCAATGATATGCCTATAACAA  
1501 ATGATCAGAAAAGTTAATGTCCAACAATGTTCAAA TAGTTAGACAGCAAAGTTACTCTA  
1561 TCATGTCCATAATAAAGAGGAAGTCTTAGCATATGTAGTACAA TTACCAC TATATGGTG  
1621 TGATAGATACACCTTGTTGGAAATTACACACATCCCCTCTATGTACAA CCAACA AAG  
1681 AAGGGTCAAACATCTGTTTAAACAAGAACTGACAGAGGATGGTACTGTGACAA TGCAGGAT  
1741 CAGTATCTTTCTTCCACAAGCTGAAACATGTAAAGTTCAATCGAATCGAGTATTTTGTG  
1801 ACACAAATGAACAGTTTAACATTACCAAGTGAAGTAAATCTCTGCAATGTTGACATATCA  
1861 ATCCCAAATATGATTGTAAAATTATGACTTCAAAAACAGATGTAAGCAGCTCCGTTATCA


8/13

## FIG.5 con't

1921 CATCTCTAGGAGCCATTGTGTCATGCTATGGCAAACTAAATGTACAGCATCCAATAAAA  
1981 ATCGTGGAATCATAAGACATTTTCTAACGGGTGTGATTATGTATCAAAATAAGGGGTGG  
2041 ACACTGTGCTGTAGGTAACACATTTATATGTAAATAAGCAAGAGGCAAAAAGTCTCT  
2101 ATGTAAAAGGTGAACCAATAAATTTCTATGACCCATTAGTATTCCCTCTGATGAAT  
2161 TTGATGCATCAATATCTCAAGTCAATGAGAAGATTAAACCAGAGTTTAGCATTTATTTCGTA  
2221 AATCCGATGAATTATTACATCATGTAAATGCTGGTAAATCAACCACAAATATCATGATAA  
2281 CTAATAATTATAGTGAATATAGTAATATTGTTATCATTAATTGCTGTTGGACTGCTCC  
2341 TATACTGTAAGGCCAGAAAGCACACCAGTCACACTAAGCAAGGATCAACTGAGTGGTATAA  
2401 ATAATTGCAATTAGTAAGCTGAAAGCTTCTAGCTAGCTAATTTTATAGCGCCGGGTA  
2461 GCTAGCTAATTTTCTTTACGTATTATATATGTAAATAACGTTACGTAAATACAAAC  
2521 AGAGAACAAGTCTAGATTTTGTACTTACATAAATGTCTGGGATAGTAAATCTATCATA  
2581 TTGAGCGGACCATCTGGTTCAGGAAAGACAGCCATAGCCAAAGACTATGGGAATATATT  
2641 TGGATTTGTGGTGTCCTACCACTAGATTTCCTCGTCCCTATGGAACGAGAGGTGTCTGA  
2701 TTACCAATTACGTTAACAGAGAGGCCATCTGGAAGGGAATAGCCGCCGGAACCTTCTAGA  
2761 ACATACTGAGTTTTAGGAAATATTACGGAACCTTCTAAACTGCTGTGAATACAGCGGC  
2821 TATTAATAATCGTATTGTGATGGATTTAACATCGACGGTGTAGAAAGTTTAAAAA  
2881 TACTTACCTGCAGAAAGCTT

9/13

Anti-RSV F Titres in the Sera of Mice  
Immunized with Different Prime / Boost Protocols




\* Placebo control animals (groups 6,7,8,) were immunized according to the protocol outlined in Table 1.

FIG. 6A

10/13

Anti-RSV F Titres in the Sera of Mice  
Immunized with Different Prime / Boost Protocols




\* Placebo control animals (groups 6,7,8,) were immunized according to the protocol outlined in Table 1.

FIG. 6B

11/13

# Anti-RSV F Titres in the Sera of Mice Immunized with Different Prime / Boost Protocols




\* Placebo control animals (groups 6,7,8,) were immunized according to the protocol outlined in Table 1.

FIG. 6C



12/13

Plaque Reduction Titres in the Sera of Mice  
Immunized with Different Prime / Boost Protocols




\* Placebo control animals (groups 6,7,8,) were immunized according to the protocol outlined in Table 1.

FIG. 7

13/13

# Cytotoxic T Lymphocyte Responses in Mice Immunized with Different Prime/Boost Antigens Including Priming with ALVAC-F



Lysis of normal BALB/c fibroblasts, BC (dashed lines) and RSV infected fibroblast cell line, BCH4 (solid lines) by the effector cells from various experimental groups with day 5 effector CTL cultures. The experimental groups include: ALVAC-F prime and subunit+alum boost (□); ALVAC-F prime and ALVAC-F boost (△); Subunit+alum prime and subunit+alum boost (◇); Irrelevant ALVAC prime and subunit+alum boost (■); Placebo+alum prime and Placebo+alum boost (▲); Live RSV prime and live RSV boost (◆); FI-RSV+alum prime and FI-RSV+alum boost (x) and Placebo (i.n.) prime and placebo (i.n.) boost (□).

FIG.8

# INTERNATIONAL SEARCH REPORT

Intern. Search No.

PCT/CA 97/00498

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K39/155

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EWASYSHYN M.E. AND KLEIN M.H.: "Prospects for Immunization Against Respiratory Syncytial Virus" VACCINE RESEARCH, vol. 2, 1993, pages 263-272, XP002044888	11-20
A	see the whole document	1-10
X	CONNORS M. ET AL.: "Respiratory Syncytial Virus (RSV) F, G, M2 (22K), and N Proteins Each Induce Resistance to RSV Challenge, but Resistance Induced by M2 and N Proteins Is Relative Short-Lived" JOURNAL OF VIROLOGY, vol. 65, 1991, pages 1634-1637, XP002047927	11-14, 19,20
A	see abstract	15-18
	---	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

24 November 1997

Date of mailing of the international search report

10. 12 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Olsen, L

## INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/CA 97/00498

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 92 01471 A (THE UAB RESEARCH FOUNDATION) 6 February 1992 see example 7	11-14, 19,20 1-10, 15-18
X  A	--- OLMSTED R.A. ET AL.: "Expression of the F glycoprotein of respiratory syncytial virus by recombinant vaccinia virus: Comparison of the individual contributions of the F and G glycoproteins to host immunity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, U.S.A., vol. 83, 1986, pages 7462-7466, XP002047928 see abstract	11-14, 19,20      15-18
X  A	--- STOTT E.J. ET AL.: "Human Respiratory Syncytial Virus Glycoprotein G Expressed from a Recombinant Vaccinia Virus Vector Protects Mice against Live-Virus Challenge" JOURNAL OF VIROLOGY, vol. 60, 1986, pages 607-613, XP002047929 see abstract	11-13, 19,20     14-18
A	--- WO 94 27636 A (AMERICAN CYANAMID CO.) 8 December 1994 see the whole document	1-10
A	--- WO 87 04185 A (UNIVERSITY OF NORTH CAROLINA) 16 July 1987 see the whole document -----	1-10

# INTERNATIONAL SEARCH REPORT

Application No.

PCT/CA 97/00498

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-10  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-10 are directed to a method of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 97/00498

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9201471 A	06-02-92	AU 650040 B	09-06-94
		AU 8330391 A	18-02-92
		CA 2087853 A	25-01-92
		EP 0540645 A	12-05-93
		HU 67362 A	28-03-95
		JP 5509231 T	22-12-93
		NZ 239084 A	27-09-94
		NZ 250402 A	28-08-95
-----			
WO 9427636 A	08-12-94	AU 676340 B	06-03-97
		AU 6957194 A	20-12-94
		EP 0705109 A	10-04-96
		FI 955667 A	12-01-96
		JP 8510749 T	12-11-96
		NO 954786 A	23-01-96
-----			
WO 8704185 A	16-07-87	AU 605476 B	17-01-91
		AU 6941287 A	28-07-87
		DE 3689622 D	17-03-94
		DE 3689622 T	16-06-94
		EP 0290446 A	17-11-88
		HK 51597 A	25-04-97
		JP 8173171 A	09-07-96
		US 5149650 A	22-09-92
-----			